Illumina gets funds for bead-based proteomic arrays:
This article was originally published in Clinica
Illumina has received a $1.2m grant from the US National Institutes of Health to continue its development of high-multiplex, low-cost arrays to profile protein activity in small volumes of cells or biological fluids. Identifying protein profiles will be valuable in a range of markets including diagnostics, said the San Diego, California firm. By profiling and understanding protein activity, pharmaceutical and biotech firms can identify more targeted drug compounds and discover relevant biomarkers for use in diagnostic products. The company added that its proprietary BeadArray technology provided the throughput, cost-effectiveness and flexibility needed to enable researchers to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.